2,147
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

ORCID Icon, , , , , , , , ORCID Icon, , , & show all
Article: 2207948 | Received 05 Dec 2022, Accepted 17 Apr 2023, Published online: 03 May 2023